• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Subclinical Atherosclerosis in Primary Sj ögren's Syndrome: Does Inflammation Matter?
Conclusions The markers of endothelial activation and damage and of chronic inflammation investigated until now failed to result predictors of subclinical atherosclerosis or to be associated with increased risk of CV events in SS patients. This may suggest that other mechanisms are implicated with increased prevalence of subclinical atherosclerosis in SS or that these biomarkers exert a different mechanism in the pathogenesis of endothelial damage and in the induction of atherosclerosis. Surely, the relationship between the disease itself and inflammatory and immune dysfunction factors is quite complex and still to be cla...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Comorbidities in patients with Primary Sj ögren's Syndrome and Systemic Lupus Erythematosus: A comparative registries‐based study
Conclusions: pSS patients have consistently less serious CV comorbidity burden and a lower prevalence of severe infection than those with SLE. In contrast, their risk of lymphoma was greater. This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - August 25, 2016 Category: Rheumatology Authors: I ñigo Rúa‐Figueroa, Mónica Fernández de Castro, José L. Andreu, Carlos Sanchez‐Piedra, Víctor Martínez‐Taboada, Alejandro Olivé, Javier López‐Longo, José Rosas, María Galindo, Jaime Calvo‐Alén, Antonio Fernández‐Nebro, Fernando A Tags: Original Article Source Type: research